Core Viewpoint - The announcement of a global strategic collaboration and licensing agreement between the company and Bristol-Myers Squibb is expected to enhance the development of next-generation bispecific antibodies, leading to significant financial benefits for the company [1] Group 1: Financial Aspects - The company will receive an upfront payment of $90 million as part of the agreement with Bristol-Myers Squibb [1] - The company is eligible for up to $1.035 billion in development and commercial milestone payments if all potential projects are advanced by Bristol-Myers Squibb [1] - Cumulatively, the company has secured over $10 billion in total collaboration agreements with multinational corporations (MNCs) [1] Group 2: Recent Collaborations - Since 2025, the company has secured three major deals with MNCs, including a significant collaboration with AstraZeneca worth 4.575 billion yuan, which also involved a $105 million equity investment [1] - In June, the company entered into a global strategic collaboration with Otsuka Pharmaceutical regarding the BCMAxCD3 bispecific T-cell engager (HBM7020) [1] - The total number of collaborations with MNCs has reached seven [1]
港股异动 | 和铂医药-B(02142)早盘涨超8% 公司与百时美施贵宝签订超10亿美元BD交易